

---

**MYELOPATHY.ORG**

---

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 30 JUNE 2021**

---

**MYELOPATHY.ORG**

---

**CONTENTS**

---

	Page
<b>Reference and administrative details of the charity, its Trustees and advisers</b>	<b>1</b>
<b>Trustees' report</b>	<b>2 - 7</b>
<b>Independent examiner's report</b>	<b>8</b>
<b>Statement of financial activities</b>	<b>9</b>
<b>Balance sheet</b>	<b>10</b>
<b>Notes to the financial statements</b>	<b>11 - 16</b>

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS  
FOR THE YEAR ENDED 30 JUNE 2021

---

**Trustees**

Dr Mark Kotter  
Lady Julia K H Carter of Coles  
Mrs Weslie R Janeway  
Ms Helen J Wood  
Dr Johann Graggaber  
Ms Carol Sun  
Mr David Townshend  
Mr Iwan Lloyd Sadler (appointed 15 March 2021)

**Charity registered number**

1178673

**Principal office**

Lakin Rose  
Pioneer House  
Vision Park  
Histon  
Cambridge  
CB24 9NL

**Independent examiners**

Lakin Rose Limited  
Pioneer House  
Vision Park  
Histon  
Cambridge  
CB24 9NL

**TRUSTEES' REPORT  
FOR THE YEAR ENDED 30 JUNE 2021**

---

The Trustees present their annual report together with the financial statements of the Myelopathy.org for the year 1 July 2020 to 30 June 2021.

**Objectives and activities**

**a. Policies and objectives**

To advance health and education in all aspects of Degenerative Cervical Myelopathy (DCM) in particular but not exclusively by:

1. Supporting and funding scientific research into all aspects of DCM and ensuring the useful results of such research are publicly disseminated.
2. Raising awareness and understanding of the condition in all its forms including sharing current research and healthcare information.
3. Supporting and promoting improved physical and mental outcomes for patients including establishing support for patients, carers and health professionals.

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

**b. Main activities undertaken to further the charity's purposes for the public benefit**

**(1) Research**

The following section summarises the projects that Myelopathy.org has been involved in which further our first charitable aim, to support research in the field of DCM. Below we have included further explanations of each of the projects which in each case are being done to better understand the condition and the best ways to treat it, in order to improve the lives of the people affected by it. We believe that this is for the future public benefit and fulfils our obligations as trustees.

**AO Spine RECODE DCM**

Myelopathy.org continues to be a partner in AO Spine RECODE DCM, an international consensus initiative to involve people with DCM alongside healthcare professionals, in the design and direction of DCM research. The top 10 research priorities have been identified and we are now involved in forming task forces to develop diagnostic criteria, understand the natural history of DCM and develop an integrated pathway for those undergoing surgery (all top 10 research priorities).



**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**Objectives and activities (continued)**
**The Top Ten Research Priorities**

	Short Title	Full Priority Wording
1	Raising Awareness	What strategies can increase awareness and understanding of DCM amongst healthcare professionals and the public? Can these strategies help improve timely diagnosis and management of DCM?
2	Natural History	What is the natural history of DCM? What is the relationship between DCM and asymptomatic spinal cord compression or canal stenosis? What factors influence the natural history of the disease?
3	Diagnostic Criteria	What are the diagnostic criteria of DCM? What is the role of imaging and when should imaging be used in the assessment of DCM?
4	Assessment and Monitoring	What assessment tools can be used to evaluate functional impairment, disability and quality of life in people with DCM? What instruments, tools or methods can be used or developed to monitor people with DCM for disease progression or improvement either before or after surgical treatment?
5	Pathophysiology	What is the pathophysiology of DCM? What are the mechanisms of neurological injury and the molecular and anatomical consequences?
6	Rehabilitation	What is the role of rehabilitation following surgery for DCM? Can structured postoperative rehabilitation improve outcome following surgery for DCM? What are the most effective strategies?
7	Novel Therapies	Can novel therapies, including stem-cell, gene, pharmacological and neuroprotective therapies, improve the health and wellbeing of people living with DCM and slow down disease progression?
8	Socio-economic Impact	What is the socio-economic impact of DCM? ( <i>The financial impact of living with DCM to the individual, their supporters and society as a whole</i> )
9	Imaging Techniques	What is the role of dynamic or novel imaging techniques and neurophysiology in the assessment of DCM?
10	Individualising Surgery	Are there clinical and imaging factors that can help a surgeon select who should undergo surgical decompression in the setting of DCM? At what stage of the disease is surgery the preferred management strategy?

These research priorities will direct future Myelopathy.org funding and strategies.

**RECEDE Myelopathy [Regeneration in Cervical Degenerative Myelopathy]**

(University of Cambridge and National Institute for Health Research)

Phase III, double blind, placebo randomised controlled efficacy study of Ibudilast (a medicine) as an additional therapy to decompressive surgery (the gold standard treatment) for DCM. Ibudilast is a medicine currently under investigation for treatment of Multiple Sclerosis, Motoneuron Disease (ALS) and Brain Tumours. Myelopathy.org continues to support this clinical research trial. Ethical approval of the trial was obtained in early 2020 but the ongoing COVID 19 pandemic has resulted in a further delay to its implementation

**POLYFIX-DCM**

(University of Cambridge and National Institute for Health Research).

Myelopathy.org is a partner and supports this clinical trial to compare two types of surgery for DCM. We have brought the voice of people with DCM to the design of this clinical trial. Recruitment to the trial is expected to commence during 2022.

**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**Objectives and activities (continued)**

**DCM Core Information Set (COINS)**

Myelopathy.org has received a grant from the Evelyn Trust to create the first comprehensive education framework for people with DCM. The aim of the project is to define key points at which people with DCM require information and the content of this. We will develop a series of Core Information Sets, 'checklists,' to help ensure professionals and people with DCM cover critical concepts at key points in their journey. This is hugely important for people with DCM and will better support shared decision making in DCM, a National Institute for Health and Care (NICE) recommendation and help to bring evidence-based care into every clinic. This will empower people with DCM to ensure their care is in-line with the latest evidence.

**(2) Awareness**

This section describes the activities of Myelopathy.org has been involved in that further our second charitable aim, to raise awareness of DCM.

**Myelopathy.org website**

Our website is our hub of information about the charity and also a vital resource for people with DCM and healthcare professionals.

**Myelopathy Matters PodCasts**

Myelopathy Matters is a PodCast series produced by Myelopathy.org. The aim of the PodCast is to bring the latest information on living with, managing and understanding DCM, through expert guests from around the world. For example, our special series covering the top 10 research priorities with AO Spine was listened to over 10,000 times.

PodCasts are a popular medium, and well suited for listeners with DCM, who may become uncomfortable sitting watching a screen for example.

**Google Ads**

Myelopathy.org has continued to benefit from the Google Ad Grant awarded during 2019-20. This has enabled Myelopathy.org to take advantage of the \$10,000 USD monthly budget of in-kind Google Ads advertising credit through the Google Ad Grants program.

Our Google Ads campaigns has focused on two key objectives in different geographical locations:

1. targeting aware groups
2. targeting non-aware groups

We are working on further developing our website and marketing efforts to help implement their recommendations to help us raise awareness and target the people we want to reach.

**(3) Support**

Our Myelopathy Support page on Facebook continues to grow and now has over 3,000 followers. Myelopathy.org also runs an on-line private support group on Facebook which has approximately 1750 members. This group helps to reduce isolation for our community and increases their knowledge of DCM. The group is run by volunteers, all of whom have DCM, and provides a unique space for our community to interact and engage on a one-to-one basis with people in similar circumstances. The group provides emotional support, social networks and educational resources. Members of the DCM community also run a peer mentoring programme where people with significant lived experience of DCM provide information and support to others during different stages of their DCM journey.

Both groups are led by Iwan Sadler, co-founder of Myelopathy.org and a person with DCM.



**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**Objectives and activities (continued)**

The Myelopathy Matters PodCast series offers the DCM community an additional platform to learn about what is happening at Myelopathy.org. The series includes information on research projects, interviews with leading healthcare professionals in the field of DCM and information from people with DCM. This helps to fulfil our objective of supporting and improving the physical and mental outcomes for people with DCM by providing a supportive and informative information source.

**Achievements and performance**

**a. Review of activities**

Below is a brief summary of the main achievements of Myelopathy.org this year.

2020-21 has been a year of consolidation for Myelopathy.org where we have focussed on developing a strategy to allow the charity to grow in a sustainable manner and move forward to continue to fulfil our charitable aims, namely, to advance health and education in all aspects of degenerative cervical myelopathy.

The Trustees provided the funding to engage an experienced charity professional in November 2020 to assist the board to produce a strategic plan for developing the charity. In particular, the strategic plan addressed fundraising, programme management, website content and design, compliance and volunteer management.

This appointment was on a consultancy basis and its success and subsequent fundraising has enabled Myelopathy.org to appoint our first member of staff. Zahabiya Karimi has been appointed as Director of Myelopathy.org and took up the role on a part-time basis on 1 July 2021.

We have appointed three new trustees to the Board of Myelopathy.org. Carol Sun is a marketing executive and David Townshend is a former investment banker who is also a qualified accountant. Our co-founder Iwan Sadler was also appointed a trustee in June 2021. Helen Wood took over the role of Chair of the Board of Trustees in November 2020.

- **Fundraising**

We successfully applied for 2 grants during 2020-21. Awards for All (part of the National Lottery) awarded us a grant and The Evelyn Trust awarded us a Health & Wellbeing grant to fund the DCM COINS project. In addition to these we have continued to receive much needed donations from our beneficiaries and their supporters together with donations (both large and small) from other donors.

Myelopathy.org's income has increased by approximately 265% in 2020-21, from £33,728 to £123,284.

As part of our strategic plan the board commissioned a Case for Support which is being used on an on-going basis to help us with our grant applications. We also started work on our first challenge event – entering a team in the Cambridge half marathon in October 2021 – to raise funds and awareness of Myelopathy.org.

- **Volunteers**

Volunteers are key to everything we do at Myelopathy.org and we could not continue to operate without their incredible support, in particular our fantastic group of volunteers (all people with DCM) who run our support group. During 2020-21 we have started to build up a professional volunteer programme to expand our capacity. This has involved creating structured processes to closely manage and maintain volunteer development. Additional volunteers have been recruited to work on the following projects; website design and re-development, charity rebranding, support group analysis, content for all areas of our work, general charity administration, grant writing and research, Human Resources and DCM COINS.

**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**Achievements and performance (continued)**

- **Operations, outreach, and communication**

During 2020-21 we have been working on Myelopathy.org's compliance which has included putting policies in place and ensuring our compliance with GDPR. In addition, we have started the process of updating our website (both design and content) and are working on a charity re-brand. The new website and re-brand will be launched in 2022. As part of this process, we have been examining how we communicate with all our stakeholders both by traditional means and via social media.

- **Programmes**

We have continued to be a partner in RECODE-DCM which has now identified the Top 10 research priorities for DCM and we are now involved in forming task forces to develop the research priorities further.

We have started work on the DCM COINS project to create the first comprehensive education framework for people with DCM.

We have continued to partner NIHR funded clinical trials to bring the voice of people with DCM to these trials.

We have continued to develop and broadcast our Myelopathy Matters PodCast series to better inform our community about the work of Myelopathy.org.

2020-21 saw the continuation of the COVID-19 global pandemic and this highlighted the need for Myelopathy.org to continue its work to inform and support our community. Our digital platform has enabled us to continue this work seamlessly but has highlighted the need to improve how we do this to best support our community who has been hard hit by the restrictions to much of normal life.

**Financial review**

**a. Going concern**

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies.

**b. Reserves policy**

At present Myelopathy.org has minimal annual liabilities. Consequently, and based on the limited annual income, it is felt that a reserve fund is not required nor possible at this time.

This position will be reviewed annually by the Trustees.

**Structure, governance and management**

**a. Constitution**

Myelopathy.org is a registered charity, number 1178673, and was incorporated on 6 June 2018.



**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**Structure, governance and management (continued)**

**b. Methods of appointment or election of Trustees**

The management of the charity is the responsibility of the Trustees who are elected and co-opted under the terms of the Constitution.

**c. Financial risk management**

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the charity, and are satisfied that systems and procedures are in place to mitigate exposure to the major risks.

**Members' liability**

The Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up.

**Statement of Trustees' responsibilities**

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on **26 April 2022** and signed on their behalf by:

Ms Helen J Wood  
Trustee

*Helen J Wood*

**INDEPENDENT EXAMINER'S REPORT  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**Independent Examiner's Report to the Trustees of Myelopathy.org ('the charity')**

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 30 June 2021.

**Responsibilities and Basis of Report**

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of our examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent Examiner's Statement**

Your attention is drawn to the fact that the charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

We understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.


We have completed our examination. We confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees as a body, for our work or for this report.

Signed:



Dated: 27 April 2022

Carla Barnes FCCA

**Lakin Rose Limited**

Pioneer House, Vision Park, Histon, CB24 9NL

**STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 30 JUNE 2021**

	Note	Restricted funds 2021 £	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
<b>Income from:</b>					
Donations	3	12,088	106,229	118,317	26,001
Charitable activities	4	-	4,946	4,946	7,727
Investments	5	-	21	21	-
<b>Total income</b>		<b>12,088</b>	<b>111,196</b>	<b>123,284</b>	<b>33,728</b>
<b>Expenditure on:</b>					
Raising funds	6	-	1,842	1,842	-
Charitable activities		7,994	65,518	73,512	29,870
<b>Total expenditure</b>		<b>7,994</b>	<b>67,360</b>	<b>75,354</b>	<b>29,870</b>
<b>Net movement in funds</b>		<b>4,094</b>	<b>43,836</b>	<b>47,930</b>	<b>3,858</b>
<b>Reconciliation of funds:</b>					
Total funds brought forward		-	8,493	8,493	4,635
Net movement in funds		4,094	43,836	47,930	3,858
<b>Total funds carried forward</b>		<b>4,094</b>	<b>52,329</b>	<b>56,423</b>	<b>8,493</b>

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 11 to 16 form part of these financial statements.

---

MYELOPATHY.ORG

---

**BALANCE SHEET  
AS AT 30 JUNE 2021**

---

	Note	2021 £	2020 £
<b>Current assets</b>			
Debtors	10	7,237	2,587
Cash at bank and in hand		54,261	6,656
		<u>61,498</u>	<u>9,243</u>
Creditors: amounts falling due within one year	11	(5,075)	(750)
<b>Net current assets</b>		<u>56,423</u>	<u>8,493</u>
<b>Total net assets</b>		<u><u>56,423</u></u>	<u><u>8,493</u></u>
<b>Charity funds</b>			
Restricted funds	12	4,094	-
Unrestricted funds	12	52,329	8,493
<b>Total funds</b>		<u><u>56,423</u></u>	<u><u>8,493</u></u>

The financial statements were approved and authorised for issue by the Trustees on  
26 April 2022 and signed on their behalf by:

Ms Helen J Wood  
Trustee

Helen Wood

The notes on pages 11 to 16 form part of these financial statements.



**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**1. General information**

The charity is a charitable incorporated organisation (CIO). The charity's address is c/o Lakin Rose, Pioneer House, Vision Park, Histon, Cambridge, CB24 9NL.

**2. Accounting policies**

**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Myelopathy.org meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

**2.2 Income**

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the statement of financial activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the balance sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

**2.3 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

**2. Accounting policies (continued)**

**2.3 Expenditure (continued)**

Expenditure on charitable activities is incurred on directly undertaking the activities which further the charity's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

**2.4 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the statement of financial activities as a finance cost.

**2.5 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

**3. Income from donations**

	<b>Restricted funds 2021 £</b>	<b>Unrestricted funds 2021 £</b>	<b>Total funds 2021 £</b>	<b>Total funds 2020 £</b>
Donations	-	106,229	<b>106,229</b>	26,001
Grants	12,088	-	<b>12,088</b>	-
	<b>12,088</b>	<b>106,229</b>	<b>118,317</b>	<b>26,001</b>
<i>Total 2020</i>	-	26,001	26,001	

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021

---

4. Income from charitable activities

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Research services	4,946	4,946	7,727

5. Investment income

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Interest receivable	21	21	-

6. Expenditure on raising funds

Costs of raising voluntary income

	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Costs of raising voluntary income	1,842	1,842	-

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021

7. Analysis of expenditure by activities

	Activities undertaken directly 2021 £	Support costs 2021 £	Total funds 2021 £	Total funds 2020 £
Charitable activities	5,964	67,548	73,512	29,870
<i>Total 2020</i>	8,424	21,446	29,870	

Analysis of direct costs

	Charitable activities 2021 £	Total funds 2021 £	Total funds 2020 £
Education	3,095	3,095	3,559
Research	2,869	2,869	4,865
	5,964	5,964	8,424

Analysis of support costs

	Charitable activities 2021 £	Total funds 2021 £	Total funds 2020 £
General office expenses	71	71	1,020
Computer expenses	768	768	647
Insurance	398	398	248
Subscriptions	157	157	157
Travel and subsistence	-	-	182
Grant funded Google advertisements	50,519	50,519	18,632
Consultancy	14,375	14,375	-
Governance costs	1,260	1,260	560
	67,548	67,548	21,446



NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021

---

**8. Independent examiner's remuneration**

The independent examiner's remuneration amounts to an independent examiner fee of £1,200 (2020 - £750).

**9. Trustees' remuneration and expenses**

During the year ended 30 June 2021, no Trustees received any remuneration or other benefits (2020 - £NIL).

During the year ended 30 June 2021, no Trustee expenses have been incurred (2020 - £NIL).

**10. Debtors**

	2021 £	2020 £
Prepayments and accrued income	149	149
Tax recoverable	5,000	2,438
Grants receivable	2,088	-
	<u>7,237</u>	<u>2,587</u>

**11. Creditors: Amounts falling due within one year**

	2021 £	2020 £
Trade creditors	1,875	-
Accruals and deferred income	3,200	750
	<u>5,075</u>	<u>750</u>

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021

12. Statement of funds

Statement of funds - current year

	Balance at 1 July 2020 £	Income £	Expenditure £	Balance at 30 June 2021 £
<b>Unrestricted funds</b>				
General Funds	8,493	111,196	(67,360)	52,329
<b>Restricted funds</b>				
Facing Myelopathy Together	-	10,000	(5,906)	4,094
DCM COINS Project	-	2,088	(2,088)	-
	-	12,088	(7,994)	4,094
<b>Total of funds</b>	<b>8,493</b>	<b>123,284</b>	<b>(75,354)</b>	<b>56,423</b>

**Facing Myelopathy Together Fund**

This fund relates to a grant from Awards for All (part of National Lottery) which is towards staff costs and website costs.

**DCM COINS Project**

This fund relates to a grant receivable from Evelyn Trust to support this project. A detailed description of this project can be found in the trustees' report.

Statement of funds - prior year

	Balance at 1 July 2019 £	Income £	Expenditure £	Balance at 30 June 2020 £
<b>Unrestricted funds</b>				
General Funds	4,635	15,096	(11,238)	8,493